The effect of GH substitution on serum lipids and lipoproteins, and in particular lipoprotein(a) (Lp(a)), was investigated in 32 adults with postoperative (acquired) GH deficiency as part of a double-blind, placebo-controlled trial. Seventeen men and fifteen women, aged 18-59 years (mean 42 years) from two centres (Hannover and Göttingen) were randomly assigned to two groups. Group P (placebo) received placebo for the first 12 months and recombinant human GH (rhGH) for the following 12 months (open phase). Group V (verum) was treated with rhGH for two consecutive periods of 12 months each. The target dose of rhGH was 2 U/m 2 per day, given subcutaneously daily at bedtime. Serum concentrations of Lp(a), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides were determined at 0, 12 and 24 months. In group V, Lp(a) increased significantly in the first as well as in the second year of treatment (P=0.02, 12 months versus baseline; P=0.016, 24 months versus 12 months). In contrast, Lp(a) levels remained unchanged in group P during the first 12 months (P=0.826 versus baseline), but increased significantly (P=0.002) during the second year, when all patients were administered GH. The increase in Lp(a) after 12 months of rhGH replacement therapy in all 32 patients was significant for Lp(a) baseline concentrations both above and below 20 mg/dl and was independent of the apolipoprotein(a) isoforms. Total and LDL-C decreased significantly after 1 year and triglycerides after 2 years in group V. A significant reduction was also observed in the TC/HDL-C and the LDL-C/HDL-C ratios. Our study shows an unfavorable effect of rhGH replacement therapy on Lp(a) levels, which is, however, counteracted by a favorable effect of rhGH on TC, LDL-C and the TC/LDL-C and LDL-C/HDL-C ratios.
Introduction
Human growth hormone (GH) is now recognized as an important hormone not only for children, but also for adults (1, 2) . Due to its beneficial effects, especially on protein synthesis and physical performance, as well as on body fat mass and on psychological well-being, the therapeutic use of GH in adults with GH deficiency (GHD) has been recommended (1) (2) (3) (4) . Before establishing GH administration as a routine therapy for GHD, particularly if long-term treatment is necessary, it is important that the metabolic effects and potential sideeffects of GH therapy are thoroughly clarified. Recent publications (5) have indicated that GH replacement therapy may be associated with increased concentrations of the plasma lipoprotein(a) (Lp(a)). The plasma concentration of Lp(a) is largely genetically determined and is inversely related to the size of the apolipoprotein(a) (apo(a)) isoform (6) . A large number of epidemiologic and case-control studies have documented an association between coronary heart disease and Lp(a) levels above a threshold concentration of 20 to 30 mg/dl. The results from prospective studies have been less clear-cut. While two reports found no association (7, 8) , a further three studies each reported Lp(a) to be an independent risk factor for coronary heart disease in hypercholesterolemic middle-aged white men (9) (10) (11) .
Short-term studies on healthy individuals (12, 13) , postmenopausal women (14) and patients with idiopathic osteoporosis (15) have consistently demonstrated that administration of GH is associated with a significant rise in serum Lp(a) concentrations. Results from the long-term application of GH in adults with acquired hypopituitarism have been less consistent. Johannsson et al. (16) , in an open prospective study of 44 patients with GHD, found a significant increase in Lp(a) after 6 and 12 months of treatment. The response to treatment was similar in patients with highmolecular weight (HMW) and low-molecular weight (LMW) apo(a) phenotypes. In an open 36-month study into the effect of GH replacement in 21 adults (17) , Lp(a) was reported to increase only in those patients with pretreatment levels >20 mg/dl. In a double-blind placebo-controlled study on 22 patients with hypopituitarism, Weaver et al. (18) found no significant increase in Lp(a) after 6 months of GH treatment, but in a subgroup of eight patients who received GH for a total of 12 months a modest but significant rise in Lp(a) was observed. In a double-blind, cross-over study of GH treatment in GHD adults, Eden et al. (19) reported a marked almost twofold increase in Lp(a) after only 6 weeks of treatment, which was sustained after 26 weeks. However, in a double-blind placebo-controlled trial on 18 patients with severe GHD no significant effect of GH replacement was observed after 2 months of treatment (20) .
In the present study the effects of 12 months and 24 months of GH replacement therapy on adults with adult-onset hypopituitarism were investigated in a 12-month double-blind, placebo-controlled trial followed by a 12-month open phase. This report focuses on the changes in serum lipid and lipoprotein concentrations and in particular Lp(a) concentrations.
Subjects and methods

Subjects
The patients recruited for this study were from two centres (Hannover and Göttingen) participating in a larger randomized double-blind placebo-controlled multicentre trial (Biosynthetic Human Growth Hormone Replacement Therapy in Adults with Acquired Growth Hormone Deficiency) for the investigation of GH substitution therapy in adult patients with acquired hypopituitarism. All patients from these two centres who were recruited into the multicentre trial were included in this present investigation. Patients from all regions of Lower Saxony (northern Germany) with known acquired hypopituitarism were screened for GHD from April 1992 to October 1993. GHD was confirmed by a serum insulin-like growth factor-I (IGF-I) level below the fifth percentile of an age-matched control group, by an insulin hypoglycemia test or an arginine hydrochloride test; diagnosis was confirmed if a flat GH response <2.0 ng/ml was observed.
Further inclusion criteria were as follows: age between 18 and 60 years; GHD acquired in adulthood at least 1 year before inclusion in the study; GHD due to a known cause (e.g. pituitary infarction or total or selective hypophysectomy for adenoma); either spontaneous normal values for thyroxine and adrenal steroids and sexual hormones, or clinically adequate replacement therapy. Sex hormone and corticoid hormone replacement therapy had to be stable for at least 3 months and thyroxine replacement therapy had to be stable for at least 1 month before inclusion in the study.
Exclusion criteria were: previous acromegaly, previous treatment with GH, diabetes mellitus (insulindependent and non-insulin-dependent), any serious chronic disease, supine blood pressure exceeding normal values of 160 mmHg systolic and/or 100 mmHg diastolic (established hypertension under adequate antihypertensive therapy revealing normal values for systolic and diastolic blood pressures was accepted), any established malignant disease or recurrent hypophyseal tumor, pregnancy or planned pregnancy during the study period, any medication or disease that might deteriorate because of GH administration or interfere with GH effects (hormone replacement due to pituitary deficiency and contraceptive use were accepted, as was bromocriptine up to 15 mg/day for treatment of prolactinoma, provided that the serum prolactin value was within the normal range), participation in a clinical trial within the preceding 3 months, initiation or change of treatment with sex steroids within the preceding 3 months, planned cessation or change of treatment with sex steroids during study.
The study was approved by the local ethics committees and written informed consent was obtained from all patients.
A total of 38 patients were included in the study. Due to a drop-out of six patients (five in the placebo group and one in the verum group), the number of patients who finished the study after 2 years was 32.
Protocol
Patients fulfilling the above criteria were randomly assigned to one of the two therapeutic regimens: group P (14 patients) received placebo injections for the first year, while group V (18 patients) was treated with recombinant human GH (rhGH; Norditropin®; Novo Nordisk, Denmark) during the first year. In the second year (open phase) both groups were treated with GH. The target dose of rhGH was 2 U/m 2 per day; mean doses in the placebo and verum groups were 2.5 U/day and 3.0 U/day respectively.
Blood samples were drawn in the morning after an overnight fast. Serum for the determination of Lp(a) concentrations and apo(a) phenotypes was separated and stored at ¹70 ЊC until assay.
Methods
Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and triglycerides were determined using commercially available kits from Boehringer Mannheim, Germany. Low-density lipoprotein cholesterol (LDL-C) was determined with a commercial kit (Quantolip LDL) from Immuno, Heidelberg, Germany. Lp(a) was quantified using a specific polyclonal noncompetitive enzyme-linked immunosorbent assay (21) . Apo(a) isoforms were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis on commercially available 4-15% polyacrylamide gradient gels (PHAST-System; Pharmacia, Freiburg, Germany) followed by immunoblotting as described elsewhere (22) . Apo(a) polymorphs were numbered 1 to 10 with increasing molecular weight (21) . A control sample containing apo(a) polymorphs 2, 4, 6 and 8 was run in three of twelve positions with each gel. Human GH (hGH) and IGF-I levels were determined using the following kits: hGH, Chemiluminescence-Immunoassay (Biermann DPC, Bad Nauheim, Germany) and IGF-I, ELISA (Nichols, Bad Nauheim, Germany). The results of hormone measurements were confirmed by reference laboratories (Dr G Brabant, Hannover, Germany for GH analysis and Dr W F Blum, Tü bingen, Germany for IGF-I determination).
Statistical analysis
Logarithmic transformation improved the skew of all lipid and lipoprotein parameters and was performed before analysis except for Lp(a). Student's paired t-test was used for comparison of values within each group and the unpaired t-test for comparisons between groups. The Wilcoxon matched-pairs signed-rank sum test was used to compare Lp(a) concentrations from repeated measurements within a group. Comparative results between the different groups (P and V) were analysed using the Mann-Whitney U test. A value of P<0.05 was considered significant.
Results
The mean age of the 32 patients (17 males and 15 females) who completed the study was 42 years and ranged from 18 to 59 years. There was no significant difference between the placebo and verum groups with regard to age, sex, body mass index (BMI), etiology and severity of hypopituitary insufficiency ( Table 1 ). The mean duration of GH deficiency did not differ between the two groups. When the patients were stratified according to duration of GH deficiency, no significant differences were observed in lipid and lipoprotein concentrations between patients with a duration <5.5 years (n=17) and those with a duration >5.5 years (n=15) (data not shown). Although mean cholesterol, LDL-C and triglyceride concentrations were somewhat higher in the verum group than in the placebo group at the start of the study, the differences were not statistically significant. Likewise no significant difference was observed between the median Lp(a) values in each group at the start of the study although values were lower in the verum group. In the verum group as well as in the placebo group, IGF-I levels prior to therapy were below the fifth percentile of an age-matched control group. After 12 months of therapy mean IGF-I levels showed a marked increase in the verum group, whereas serum concentrations remained constant in the placebo group (Table 2) .
Serum Lp(a) concentrations displayed a significant increase in the group of patients who received GH substitution during the first 12 months of this study ( Fig. 1 and Table 2 ). Of the 18 patients who received GH, an increase in Lp(a) of >10% was seen in 13/18 patients (Fig. 1) . In contrast, Lp(a) levels remained relatively stable over the first 12 months in those patients who were given a placebo ( Fig. 1 and Table 2 ). Despite the significant increase in Lp(a) in the verum group, no significant difference was observed in Lp(a) levels between the serum and placebo groups after 1 year. During the second year when the patients from the placebo group were also administered GH, a significant rise in Lp(a) occurred, 12/14 patients showing an increase in Lp(a) of >10%. Therapy with GH was continued in the verum group during the second year and this resulted in a further significant rise in Lp(a) (Fig. 1) .
The influence of gender, baseline Lp(a) concentration and apo(a) phenotype on the GH-associated increase in Lp(a) after 12 months of GH substitution was investigated in all 32 patients (Table 3) . Although median Lp(a) concentrations were lower in males than in females at baseline, the difference was not significant. However, a significant increase in serum Lp(a) levels after 12 months of GH therapy was observed in both males and females although the increase in males appeared to be more substantial than that in females. In the nine patients with baseline Lp(a) concentrations >20 mg/dl before GH substitution, a significant rise in Lp(a) was observed after 12 months of therapy. Likewise, there was a significant increase in the serum Lp(a) concentration for those 23 stratified into a LMW group, including all those patients who had at least one of the apo(a) isoforms 1-6, and a HMW group, comprising all subjects with only isoforms 7-10, a significant increase in Lp(a) was observed in both groups.
A significant decrease in both TC and LDL-C concentrations occurred in the verum group after 12 months of substitution therapy with GH (Table 2) , and this decrease was sustained over the following 12 months of therapy. As a consequence, the TC/HDL-C (28) 337 (126)*** 367 (190)*** * P < 0:05, ** P < 0:01, *** P < 0:001 compared with 0 month; † P < 0:05, † P < 0:01, † † † P < 0:001 compared with 12 months. and LDL-C/HDL-C ratios, both established strong predictors of coronary risk (23, 24) , decreased significantly in the verum group during therapy. While a reduction in serum triglycerides was observed in the verum group during the first 12 months of therapy, this decrease only reached statistical significance after 24 months. Serum lipid and lipoprotein parameters remained relatively constant (Table 2) in the placebo group during the initial 12 months. During the next 12 months when these patients also received GH, a trend to lower LDL-C levels and a reduction in the TC/HDL-C and LDL-C/HDL-C ratios was observed, although the changes were not significant. The effect of 12 months of GH substitution therapy on serum lipids and lipoproteins was assessed in all 32 patients (Table 4) . This collective GH treatment was associated with significant decreases in the serum cholesterol and LDL-C concentrations, and the TC/HDL-C and LDL-C/ HDL-C ratios, as well as with a significant increase in the serum HDL-C concentration.
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To exclude the possibility that these alterations in the lipoproteins were related to changes in body composition, we also compared the BMI (measured in kg/m 2 ) and the waist-hip ratio in the two groups during therapy. The mean BMI did not change significantly in either of the two groups. Values at 0, 12 and 24 months were 27.5, 27.0 and 27.6 respectively in the verum group and 26.7, 26.7 and 26.6 respectively in the placebo group. Likewise, the mean waist-hip ratios also remained constant. The ratios for the verum group at 0, 12 and 24 months were 0.92, 0.89 and 0.89 respectively, and in the placebo group 0.91, 0.91 and 0.89 respectively. 6.1 10.4 * P < 0:05, ** P < 0:01, *** P < 0:001 compared with before GH therapy. † LMW phenotypes 1-6/1-10; HMW phenotypes 7-10/7-10.
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Table 4
Effect of 12 months of GH substitution therapy in all 32 patients on serum lipid and lipoprotein concentrations and the LDL-C/HDL-C ratio. Data are presented as mean (S.D.).
Before GH therapy After 1 year GH therapy
Cholesterol (mg/dl) 253 (55) 231 (53)** Triglycerides (mg/dl) 185 (119) 154 (85) LDL-C (mg/dl) 181 (51) 159 (53)** HDL-C (mg/dl) 41 (14) 45 (12)* TC/HDL-C 6.8 (2.8) 5.5 (2.0)*** LDL-C/HDL-C ratio 4.8 (1.9) 3.8 (1.9)*** * P < 0:05, ** P < 0:01, *** P < 0:001.
Discussion
The results from this placebo-controlled, double-blind 12-month study in 32 adults with acquired GHD followed by a 12-month open phase demonstrated that GH replacement therapy can lead to a significant and sustained increase in serum Lp(a) concentrations. Thus, during the first 12 months a significant rise in Lp(a) was only observed in the verum group, whereas Lp(a) levels remained relatively constant in those patients administered a placebo. During the following 12-month open phase, in which all 32 patients received GH, Lp(a) concentrations now displayed a significant increase in the group of patients who had previously received a placebo. A further significant increase in Lp(a) also occurred in the original verum group during the second year of treatment with GH. The finding that GH treatment in GHD adults leads to an increase in Lp(a) concentrations is in accordance with the results of a previous placebo-controlled cross-over trial in nine patients in whom Lp(a) levels were found to be elevated after 1.5 and 6 months of therapy (10), and data from an open study on 44 patients (16) in which a significant elevation of Lp(a) in GHD subjects was reported after 12 months of GH treatment. Our data, however, conflict with those of Russell-Jones et al. (20) who detected no change in Lp(a) after 2 months of GH treatment in a double-blind placebo-controlled trial on 18 GHD adults. In another placebo-controlled double-blind study in 22 patients (18) , no significant effect of GH on Lp(a) was found after 6 months exposure to GH. However, in a subgroup of patients treated for 12 months, serum Lp(a) increased significantly. Discrepancies between these studies may be due to duration of treatment, differences in the patients recruited into the studies, differences in co-medication or differences in the assays for Lp(a). The fact that we observed a further significant increase in Lp(a) during the second year of GH treatment in the verum group indicates that the duration of therapy may be important when studying the effects of GH on Lp(a). Account must also be taken of the complexity of the metabolic situation in adults with GHD. Thus Olivecrona et al. (15) have shown that GH and IGF-I have contrasting effects on Lp(a). Treatment with IGF-I was found to reduce Lp(a) concentrations, while GH caused an elevation in Lp(a), even though the levels of IGF-I were also increased by GH. In our GHD patients, supplementation with GH also led to a marked increase in serum IGF-I concentrations. However, the overall effect on Lp(a) was an increase in Lp(a) concentrations, corroborating the observations of Olivecrona et al. (15) . In considering the influence of GH on Lp(a), the potential influence of apo(a) phenotype must also be considered, since serum Lp(a) concentrations are inversely related to the size of the apo(a) isoform (6). Garry et al. (17) reported a significant increase in Lp(a) after 2 and 3 years of therapy with GH only in those individuals with baseline Lp(a) levels above 20 mg/dl. In our study, however, neither the baseline Lp(a) concentration nor the apo(a) phenotype was found to influence Lp(a) response to GH treatment. Our data therefore support the observations from short-term GH treatment in healthy volunteers (14) and long-term treatment in GHD adults (16) . These data indicate that the stimulatory effect of GH on Lp(a) concentrations is independent of the regulation of Lp(a) concentrations through the apo(a) phenotype.
The clinical significance of GH-induced alterations of Lp(a) levels must be considered together with other alterations in the cardiovascular risk profile under GH replacement therapy (e.g. cholesterol and glucose metabolism). Untreated GHD is associated with an unfavorable lipoprotein profile consisting of elevated levels of TC, LDL-C and triglycerides, and decreased HDL-C (25, 26) whereas in patients with GH excess (acromegaly) relatively low cholesterol levels have been found (27) . In this context it should be noted that the evaluation of GH replacement therapy with regard to alterations in the cardiovascular risk profile is complicated by the fact that GHD and hypopituitarism, in spite of an adequate substitution therapy (thyroxine, sex steroids and cortisone) (28-31) as well as GH excess (acromegaly), are associated with an increased vascular and cardiac morbidity and mortality (32) . Numerous studies in adult patients with GHD (5, (16) (17) (18) (33) (34) (35) (36) (37) (38) , in adults without GHD (39, 40) as well as in children with GHD (41-43) have revealed that low-dose GH replacement therapy can reverse these alterations in the lipopotein profile. In the present investigation we also found that GH treatment led to a reduction in cholesterol and LDL-C levels as well as a small but significant rise in HDL-C. Consequently, there was a marked reduction in the TC/HDL-C and LDL-C/HDL-C ratios. The ratio of TC/HDL-C proved to be a significant independent predictor for the risk of myocardial infarction in a prospective study (24) . In this study a change of 1 U in the TC/HDL-C ratio was associated with a 53% change in risk, after adjustment for other risk factors. Results of case control studies (44, 45) have suggested that elevated Lp(a) concentrations are particularly associated with cardiovascular disease in the presence of hypercholesterolemia. Although conflicting conclusions about the association between Lp(a) and the risk of coronary heart disease have been drawn from prospective studies, these discrepancies may be due in part to differences in patient selection and study design. In the case of the Physicians Health Study (8) participants were on average 10 years older and had lower cholesterol levels than in the four other studies (7, (9) (10) (11) . In this respect it must be noted that, in a crosssectional study of cardiovascular risk factors in men and women 60 years of age and older (46) , Lp(a) was not associated with cardiovascular disease. In three prospective studies, however, Lp(a) was found to be a risk factor for coronary heart disease in middle-aged hypercholesterolemic men (9) (10) (11) . In particular, data from the Göttingen Risk Incidence and Prevalence Study (10) support the view that the individual risk as derived from LDL-C is strongly augmented if Lp(a) is also elevated. In the light of these studies it appears feasible that the beneficial effect of GH replacement on TC and LDL-C concentration may well offset the negative influence on Lp(a) levels from a cardiovascular standpoint.
Further studies are necessary to fully evaluate the long-term clinical consequences of the changes in the cardiovascular risk induced by GH replacement therapy. We would recommend monitoring of Lp(a) concentrations in patients undergoing GH replacement therapy, especially in patients with relatively high or elevated baseline values of Lp(a) and concomitantly elevated TC and LDL-C concentrations.
